echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China Resources Seko's pyridhan hydrochlorochlorine tablets were evaluated by generic consistency.

    China Resources Seko's pyridhan hydrochlorochlorine tablets were evaluated by generic consistency.

    • Last Update: 2020-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: Pythatan hydrochlorophenic tablet adaptation: treatment of a single drug can not fully control blood pressure of mild-moderate primary hypertension.
    . On September 15, China Resources Shuanghe announced that its wholly-owned subsidiary, China Resources Seko Pharmaceutical Co., Ltd., had received a "Notice of Approval of Drug Supplemental Application" issued by the State Drug Administration for the approval of the drug through the quality and efficacy of generic drugs.
    : Treatment of mild-moderate primary hypertension that does not adequately control blood pressure with a single drug.
    China Resources Seko initiated the consistency evaluation of the drug in November 2017, submitted a conformity evaluation application to the State Drug Administration on November 5, 2019, received a notice of acceptance on November 20, 2019, and approved it by the State Drug Administration on September 3, 2020, and is the second company to pass the drug consistency evaluation.
    date of this announcement, China Resources Seko has invested RMB17.2533 million (unaudited) in research and development for the consistent evaluation of the drug.
    was first developed by Novartis Pharma Schweiz AG in Switzerland and was approved by the FDA in 1998 to be listed in the United States under the name DIOVAN HCT ®.
    the U.S., the main producers of Pyrochlorophenidate are NOVORTIS, AUROBINDO PHARMA LTD, LUPIN LTD, etc., and the Diovan Group has annual global sales of $1,064 million, according to the 2019 annual report released by Novartis Pharmaceuticals of Switzerland.
    chinese company, was launched in China in 2005 and the imported drug manufacturer is Novortis Farma S.p.A. (I), with the trade name "Fudaiwen".
    According to data from Guangdong Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics, the total sales of pyridoxine tablets in The Chinese market in 2019 amounted to RMB1.15 billion;
    2019, China Resources Seko's sales revenue from the drug was RMB13,146.27 million (audited).
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.